Botanix Pharmaceuticals Ltd
ASX:BOT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.11
0.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
BOT
stock under the Base Case scenario is
0.563
AUD.
Compared to the current market price of 0.115 AUD,
Botanix Pharmaceuticals Ltd
is
Undervalued by 80%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Botanix Pharmaceuticals Ltd.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
A delay or failure in Botanix’s clinical trials for its leading synthetic cannabinoid therapies would significantly undermine investor confidence, given that the company’s core revenue potential relies on successful product approvals for conditions like acne and dermatitis.
Highly competitive dermatology and cannabinoid-based therapeutics markets threaten Botanix’s ability to secure sufficient market share upon commercialization, especially as larger pharmaceutical firms introduce rival cannabinoid or transdermal innovations.
The company’s modest cash reserves and reliance on external funding for research and development could introduce substantial dilution risk for shareholders if trials become more expensive or require additional phases.
Botanix’s proprietary Permetrex technology, designed to enhance the skin penetration of its synthetic cannabinoid formulations, provides a potential competitive advantage in drug delivery and differentiation from other dermatology players.
Early clinical data suggesting efficacy in treating acne and atopic dermatitis positions Botanix to capture significant market share once regulatory approvals are obtained, thanks to the growing demand for more advanced topical solutions.
Management’s focus on strategic partnerships and out-licensing opportunities could accelerate commercialization and mitigate funding risks, leveraging larger pharmaceutical partners’ resources to support late-stage trials and product launches.
Revenue & Expenses Breakdown
Botanix Pharmaceuticals Ltd
Balance Sheet Decomposition
Botanix Pharmaceuticals Ltd
| Current Assets | 99.6m |
| Cash & Short-Term Investments | 65m |
| Receivables | 3.2m |
| Other Current Assets | 31.4m |
| Non-Current Assets | 29.5m |
| PP&E | 1.4m |
| Intangibles | 28.1m |
| Other Non-Current Assets | -100 |
| Current Liabilities | 24.9m |
| Accounts Payable | 11.7m |
| Accrued Liabilities | 1.9m |
| Other Current Liabilities | 11.3m |
| Non-Current Liabilities | 22.9m |
| Long-Term Debt | 22.9m |
Free Cash Flow Analysis
Botanix Pharmaceuticals Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Botanix Pharmaceuticals Ltd
|
Revenue
|
5.8m
AUD
|
|
Cost of Revenue
|
-3.6m
AUD
|
|
Gross Profit
|
2.1m
AUD
|
|
Operating Expenses
|
-90.2m
AUD
|
|
Operating Income
|
-88m
AUD
|
|
Other Expenses
|
1.6m
AUD
|
|
Net Income
|
-86.4m
AUD
|
BOT Profitability Score
Profitability Due Diligence
Botanix Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Botanix Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
BOT Solvency Score
Solvency Due Diligence
Botanix Pharmaceuticals Ltd's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Score
Botanix Pharmaceuticals Ltd's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BOT Price Targets Summary
Botanix Pharmaceuticals Ltd
Dividends
Current shareholder yield for
BOT is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BOT
stock under the Base Case scenario is
0.563
AUD.
Compared to the current market price of 0.115 AUD,
Botanix Pharmaceuticals Ltd
is
Undervalued by 80%.